TG Therapeutics | TGTX - Interest Expense On Debt


TG Therapeutics reported $6.72M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alaunos Therapeutics USD 0 0 Dec/2023
Amgen USD 653M 32M Dec/2025
Ardelyx USD 5.8M 784K Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Curis USD 178K 441K Dec/2023
Gilead Sciences USD 255M 1000K Dec/2025
Infinity Pharmaceuticals USD 45K 0 Jun/2023
J&J USD 18M 290M Sep/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Novartis USD 281M 8M Sep/2025
Novavax USD 4.24M 96K Sep/2024
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 6.72M 4K Sep/2025
Verastem USD 1.15M 10K Sep/2024
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025